Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System
Low Prices Seen Part Of Wider Problem
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.
You may also be interested in...
The Japanese firm has decided to shrink its oncology portfolio by transferring its rights to oxaliplatin in Japan, along with a portfolio of generics, to Takata. Though Yakult will maintain an interest in the area through irinotecan and several other anticancers, its has said future R&D investment will shift more towards the microbiome.
To stabilize now years-old pharmaceutical supply shortages, especially from generic firms, Japan will review several regulations related to the sector and aspects of its reimbursement pricing scheme. Recently announced economic policies and an official report also refer to potential measures to encourage businesses through financial support and revised pricing premiums.
Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, tells Scrip in the first of a two-part exclusive interview about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.